A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy

British Journal of Clinical Pharmacology

Volumn 81, Issue 6, 2016, Pages 1058-1066

  Ahmed, Mariam A ^a,b,c   Kartha, Reena V ^a,b   Brundage, Richard C ^a,b   Cloyd, James ^a,b   Basu, Cynthia ^b   Carlin, Bradley P ^b   Jones, Richard O ^d   Moser, Ann B ^d   Fatemi, Ali ^d   Raymond, Gerald V ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Ein Helwan   (Egypt)

^d KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

erucic acid; inborn errors of metabolism; nonmem; population pharmacodynamics

Indexed keywords

ERUCIC ACID; LORENZO OIL; DRUG COMBINATION; FATTY ACID; TRIOLEIN;

ADRENOLEUKODYSTROPHY; ARTICLE; ASYMPTOMATIC DISEASE; CHILD; CHILDHOOD DISEASE; DRUG EXPOSURE; DRUG RESPONSE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; X LINKED ADRENOLEUKODYSTROPHY; BIOLOGICAL MODEL; BLOOD; BRAIN; CLINICAL TRIAL; DRUG COMBINATION; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ADRENOLEUKODYSTROPHY; BRAIN; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ERUCIC ACIDS; FATTY ACIDS; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MODELS, BIOLOGICAL; NEUROIMAGING; TRIOLEIN;

EID: 84963558346     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12897     Document Type: Article

References (30)

1. Kemp S, Valianpour F, Denis S, Ofman R, Sanders RJ, Mooyer P, Barth PG, Wanders RJ,. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol Genet Metab 2005; 84: 144-51.
2. Aubourg P,. X-linked adrenoleukodystrophy. Ann Endocrinol (Paris) 2007; 68: 403-11.
3. Kaiser E, Kramar R,. Clinical biochemistry of peroxisomal disorders. Clin Chim Acta 1988; 173: 57-80.
4. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP,. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol 1975; 32: 577-91.
5. Kemp S, Berger J, Aubourg P,. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta 1822; 2012: 1465-74.
6. Odone A, Odone M,. Lorenzo's oil: a new treatment for adrenoleukodystrophy. J Pediatr Neurosci 1989; 5: 55-61.
7. Bourre J, Daudu O, Baumann N,. Nervonic acid biosynthesis by erucyl-CoA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-CoAs (mono and polyunsaturated). Biochim Biophys Acta 1976; 424: 1-7.
8. Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME, Jennings SS, Davis S, Jaitly R, Sgro JA,. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989; 39: 1415-22.
9. Grice H, Heggtveit H,. Relevance to humans of myocardial lesions induced in rats by marine and rapeseed oils. In: High and low erucic acid rapeseed oils: production, usage, chemistry, and toxicological evaluation, eds, Kramer JKG, Sauer FD, Pigden WJ, Toronto: Academic Press, 1983.
10. Kickler TS, Zinkham WH, Moser A, Shankroff J, Borel J, Moser H,. Effect of erucic acid on platelets in patients with adrenoleukodystrophy. Biochem Mol Med 1996; 57: 125-33.
11. Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J, Jones RO, Loes DJ, Melhem ER, Dubey P, Bezman L, Brereton NH, Odone A,. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 2005; 62: 1073-80.
12. Moser HW, Raymond GV, Koehler W, Sokolowski P, Hanefeld F, Korenke GC, Green A, Loes DJ, Hunneman DH, Jones RO,. Evaluation of the preventive effect of glyceryl trioleate-trierucate ("Lorenzo's oil") therapy in X-linked adrenoleukodystrophy: results of two concurrent trials. In: Peroxisomal Disorders and Regulation of Genes. New York: Springer: Springer Science+ Business Media, 2003; 369-87.
13. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S, Moser HW,. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999; 45: 100-10.
14. Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, Lockman L, Latchaw RE, Krivit W,. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994; 15: 1761-6.
15. Beal S, Sheiner L, Boeckmann A, Bauer R,. NONMEM User's Guides (1989-2009). Ellicott City MD: Icon Development Solutions, 2009.
16. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1998; 58: 51-64.
17. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team. 2010. nlme: linear and nonlinear mixed effects models. R package version 3.1-97. R Foundation for Statistical Computing, Vienna, 2011.
18. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
19. Allison PD,. Survival analysis using SAS: a practical guide. Cary, North Carolina: SAS Institute, 2010.
20. Akaike H, Likelihood of a model and information criteria. J Econ 1981; 16: 3-14.
21. Ekstrom C.,. MESS: Miscellaneous Esoteric Statistical Scripts. R package version 0.3-2, 2014.
22. Therneau T,. A package for survival analysis in S. R package version 2.37-4 [Online]. Available at http://CRAN.R-project.org/package=survival. Box 2013; 980032: 23298-0032 (last accessed 9 June 2013).
23. Savic RM, Karlsson MO,. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-69.
24. Berger J, Pujol A, Aubourg P, Forss-Petter S,. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20: 845-56.
25. Aubourg P, Adamsbaum C, Lavallard-Rousseau M, Rocchiccioli F, Cartier N, Jambaque I, Jakobezak C, Lemaitre A, Boureau F, Wolf C,. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med 1993; 329: 745-52.
26. Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW,. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res 1994; 19: 1073-82.
27. Poulos A, Gibson R, Sharp P, Beckman K, Rattan-Smith PG,. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994; 36: 741-6.
28. Golovko MY, Murphy EJ,. Uptake and metabolism of plasma-derived erucic acid by rat brain. J Lipid Res 2006; 47: 1289-97.
29. Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, Singh I,. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 2003; 14: 425-39.
30. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, Aubourg P,. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet 2005; 14: 1293-303.